Product Description
LY03020, a dual TAAR1/5-HT2CR agonist, is intended to treat schizophrenia and Alzheimer's disease psychosis (ADP). Developed on Luye Pharma's New Chemical Entity/New Therapeutic Entity (NCE/NTE) platform, LY03020 is a next-generation antipsychotic and the first agonist against both the trace amine-associated receptor 1 (TAAR1) and the 5-HT2C receptor (5-HT2CR) in the world. (Sourced from: https://www.marketscreener.com/quote/stock/LUYE-PHARMA-GROUP-LTD-16860092/news/Luye-Pharma-Dual-TAAR1-5-HT2CR-Agonist-LY03020-Approved-for-Clinical-Trials-in-China-47562014/)
Mechanisms of Action: 5-HT2C Agonist,5-HT1C Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shandong Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|